section name header

Pronunciation

zole-mi-TRIP-tan

Classifications

Therapeutic Classification: vascular headache suppressants

Pharmacologic Classification: five ht1 agonists

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed (40%) following oral and intranasal administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver; some conversion to metabolites that are more active than zolmitriptan. 8% excreted unchanged in urine.

Half-life: 3 hr (for zolmitriptan and active metabolite).

Time/Action Profile

(relief of headache)

ROUTEONSETPEAKDURATION
POunknown1.5 hr*unknown
Intranasalunknown3 hrunknown

*3 hr for orally disintegrating tablets.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, chest pain/pressure/tightness/heaviness, hypertension, MI, palpitations.

Derm: sweating, warm/cold sensation.

EENT: throat pain/tightness/pressure.

GI: dry mouth, dyspepsia, dysphagia, nausea.

MS: myalgia, myasthenia.

Neuro: dizziness, drowsiness, hypesthesia, paresthesia, vertigo, weakness.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Hepatic Impairment

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zomig, Zomig-ZMT

Canadian Brand Names

Zomig Rapimelt